RECRUITING

Brain Stimulation and Decision-making

Conditions

Depression Transcranial magnetic stimulation (TMS)Temporal Interference (TI)

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Decision-making is an important process that is frequently shown to be impaired in patients with depression. While a number of preclinical and clinical studies have identified key regions involved in this process, it remains unclear exactly how these regions are influencing choice behavior especially when choices become more challenging. The goal of this project is to understand how these regions, such as the cingulate cortex, impact difficult choice behavior. Specifically, the researchers are interested in learning how disruptions in cognitive control might impact choice preferences during difficult decisions in depressed patients. To do this, this study will recruit participants with depression (as well as healthy controls) to perform game-like tasks in the laboratory while undergoing TMS or TI.

Official Title

Brain Stimulation Studies of Decision-making Using Repetitive Transcranial Magnetic Stimulation (rTMS) and Temporal Interference (TI)

Quick Facts

Study Start:2019-11-11

Study Completion:2026-03

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT04099056

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 50 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:Yes

Standard Ages:ADULT

Inclusion Criteria	Exclusion Criteria
* Provides written informed consent * Fluent English speaker * Absence of current drug use as assessed by subject history and/or urine drug screen	* Pregnant or currently breast-feeding women or any woman of childbearing potential who is seeking to become pregnant or suspects that she may be pregnant, as assessed by subject report and/or urine pregnancy screen * Contraindications to fMRI scanning (including presence of a cardiac pacemaker or pacemaker wires, metallic particles in the body, vascular clips in the head or previous neurosurgery, prosthetic heart valves, claustrophobia) as assessed with the standard MRI screening form from the Facility for Research and Education in Neuroscience (FERN) * Unable to fit comfortably in the scanner * Contraindication to TMS, including history or family history of epilepsy, metallic implants in the head and/or neck, brain stimulators, vagus nerve stimulators, ventriculoperitoneal (VP) shunt, pacemakers * Current use of medications that may increase the risk of seizures (e.g., bupropion, varenicline, chlorpromazine, theophylline) or reduce the effects of rTMS, such as benzodiazepines * History or current serious or unstable medical illness, including cardiovascular, hepatic, renal, respiratory, endocrine, neurologic or hematologic disease, as assessed by subject history * Not right-handed as assessed by the Chapman handedness inventory or self report * History of head injury resulting in more than brief loss of consciousness, as assessed by subject history * History of cocaine or stimulant use (e.g., amphetamine, cocaine, methamphetamine), as assessed by subject history * History of use of dopaminergic drugs (including methylphenidate or other stimulant medication), as assessed by subject history * Current use or more than occasional use in the past year of tobacco products including cigarettes, e-cigarettes, cigars, snuff and chewing tobacco, or nicotine replacement products such as gum or patches, as assessed by subject history * Evidence of significant inconsistencies in self-report measures * Anything above minimal risk for suicide, as assessed during the clinical interview (SCID) at screening and the Columbia Suicide Severity Rating Scale (C-SSR). C-SSRS risk will be assessed as any score \> 3. * Any physical or neuropsychiatric conditions that may worsen by and/or prevent walking or running. * Meet criteria for current psychotic disorders, bipolar disorders, or severe substance use disorders as assessed by the Mini International Neuropsychiatric Interview. * Used psychotropic medications within the last six weeks as assessed by subject history. * Anything above minimal risk for suicide, as assessed during the clinical interview (SCID) at screening and the Columbia Suicide Severity Rating Scale (C-SSRS) * A symptom severity score of at least 11, as assessed by the Beck Depression Inventory (BDI)-II * History or current diagnosis of any of the following Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV psychiatric illnesses: * Organic mental disorder * Schizophrenia spectrum disorders * Delusional disorder * Psychotic disorders not otherwise specified * Patients with mood congruent or mood incongruent psychotic features * Patients with bipolar mood disorders * Substance dependence * Substance abuse within the last 12 months (with the exception of cocaine or stimulant abuse; which will lead to exclusion * Absence of any psychotropic medications for at least 2 weeks. No patient will be asked to discontinue or otherwise interrupt any psychotropic medications to participate in this study. The listed "washout" periods are only applicable for patients who previously used psychotropic medications, but recently decided to discontinue their use for some other reason. * 6 weeks for fluoxetine * 6 months for neuroleptics * 2 weeks for benzodiazepines * 2 weeks for any other antidepressants * Any current or past history of any DSM-IV psychiatric illnesses, presence of a DSM-IV psychiatric disorder within a first-degree relative, or current or past use of psychotropic medications * Score no greater than 10 on the BDI-II * Score \> 1 on the SHAPS

Inclusion Criteria

Exclusion Criteria

* Provides written informed consent
* Fluent English speaker
* Absence of current drug use as assessed by subject history and/or urine drug screen

* Pregnant or currently breast-feeding women or any woman of childbearing potential who is seeking to become pregnant or suspects that she may be pregnant, as assessed by subject report and/or urine pregnancy screen
* Contraindications to fMRI scanning (including presence of a cardiac pacemaker or pacemaker wires, metallic particles in the body, vascular clips in the head or previous neurosurgery, prosthetic heart valves, claustrophobia) as assessed with the standard MRI screening form from the Facility for Research and Education in Neuroscience (FERN)
* Unable to fit comfortably in the scanner
* Contraindication to TMS, including history or family history of epilepsy, metallic implants in the head and/or neck, brain stimulators, vagus nerve stimulators, ventriculoperitoneal (VP) shunt, pacemakers
* Current use of medications that may increase the risk of seizures (e.g., bupropion, varenicline, chlorpromazine, theophylline) or reduce the effects of rTMS, such as benzodiazepines
* History or current serious or unstable medical illness, including cardiovascular, hepatic, renal, respiratory, endocrine, neurologic or hematologic disease, as assessed by subject history
* Not right-handed as assessed by the Chapman handedness inventory or self report
* History of head injury resulting in more than brief loss of consciousness, as assessed by subject history
* History of cocaine or stimulant use (e.g., amphetamine, cocaine, methamphetamine), as assessed by subject history
* History of use of dopaminergic drugs (including methylphenidate or other stimulant medication), as assessed by subject history
* Current use or more than occasional use in the past year of tobacco products including cigarettes, e-cigarettes, cigars, snuff and chewing tobacco, or nicotine replacement products such as gum or patches, as assessed by subject history
* Evidence of significant inconsistencies in self-report measures
* Anything above minimal risk for suicide, as assessed during the clinical interview (SCID) at screening and the Columbia Suicide Severity Rating Scale (C-SSR). C-SSRS risk will be assessed as any score \> 3.
* Any physical or neuropsychiatric conditions that may worsen by and/or prevent walking or running.
* Meet criteria for current psychotic disorders, bipolar disorders, or severe substance use disorders as assessed by the Mini International Neuropsychiatric Interview.
* Used psychotropic medications within the last six weeks as assessed by subject history.
* Anything above minimal risk for suicide, as assessed during the clinical interview (SCID) at screening and the Columbia Suicide Severity Rating Scale (C-SSRS)
* A symptom severity score of at least 11, as assessed by the Beck Depression Inventory (BDI)-II
* History or current diagnosis of any of the following Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV psychiatric illnesses:
* Organic mental disorder
* Schizophrenia spectrum disorders
* Delusional disorder
* Psychotic disorders not otherwise specified
* Patients with mood congruent or mood incongruent psychotic features
* Patients with bipolar mood disorders
* Substance dependence
* Substance abuse within the last 12 months (with the exception of cocaine or stimulant abuse; which will lead to exclusion
* Absence of any psychotropic medications for at least 2 weeks. No patient will be asked to discontinue or otherwise interrupt any psychotropic medications to participate in this study. The listed "washout" periods are only applicable for patients who previously used psychotropic medications, but recently decided to discontinue their use for some other reason.
* 6 weeks for fluoxetine
* 6 months for neuroleptics
* 2 weeks for benzodiazepines
* 2 weeks for any other antidepressants
* Any current or past history of any DSM-IV psychiatric illnesses, presence of a DSM-IV psychiatric disorder within a first-degree relative, or current or past use of psychotropic medications
* Score no greater than 10 on the BDI-II
* Score \> 1 on the SHAPS

Contacts and Locations

Study Contact

Michael Treadway, PhD

CONTACT

404 727-3166

tread.lab.cbid@emory.edu

Principal Investigator

Michael Treadway, PhD

PRINCIPAL_INVESTIGATOR

Emory University

Study Locations (Sites)

Emory University

Atlanta, Georgia, 30322

United States

Collaborators and Investigators

Sponsor: Emory University

Michael Treadway, PhD, PRINCIPAL_INVESTIGATOR, Emory University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2019-11-11

Study Completion Date2026-03

Study Record Updates

Study Start Date2019-11-11

Study Completion Date2026-03

Terms related to this study

Keywords Provided by Researchers

Transcranial magnetic stimulation (TMS)
Temporal Interference (TI)

Additional Relevant MeSH Terms

Depression